Xtant Medical Holdings, Inc. — Form 8-K
Filed August 11, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 68/100
What the filing says
Xtant Medical reported Q2 2026 revenue of $23.0M vs. $35.4M in Q2 2025, a 35% decline driven by the December 2025 sale of Coflex/CoFix assets to Companion Spine and cessation of high-margin license revenue. The company acquired exclusive U.S. commercial rights to Dilon Technologies' HEMOBLAST Bellows hemostasis product for $5.0M exclusivity fee and hired ~20 Dilon salespeople. Net loss was $9.4M (vs. +$3.6M net income in Q2 2025); adjusted EBITDA fell to -$2.7M from +$6.9M. Cash declined to $9.9M; full-year guidance reduced to $99–$103M from $101–$105M.
Why this rating
Revenue collapse (35% YoY) and swing to quarterly net loss are material relative to ~$45M market cap; $5M exclusivity bet on unproven product (11% of cap) is high-risk. Cash down 43% in 6 months; debt still $23M. Divestiture + market headwinds signal strategic retreat. However, biologics pivot and sales-force add offer future upside. Significant deterioration requires close watch.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.